Thiazolidinedione (TZD) insulin sensitizers are specific agonists of peroxisome proliferator activated receptor (PPAR)␥. However, their mechanism of action and the in vivo target tissue(s) that mediate insulin sensitization remain poorly defined. Although PPAR␥ messenger RNA expression has been reported in skeletal muscle, the expression of PPAR␥ within myocytes in intact muscle tissue has not been examined. An antipeptide PPAR␥ antibody was generated; immunohistochemistry was then used to demonstrate that PPAR␥ is present within nuclei of myocytes [in both skeletal (white and red fibers) and cardiac tissue (rodent and human)]. The effect of insulin sensitizer treatment on muscle insulin action was studied using ob/ob mice after 4 days dosing with a potent (6 nM PPAR␥ K d ) TZD (10 mg/kg⅐day). 2-deoxyglucose (2-DOG) uptake was then assessed in freshly isolated soleus muscles from lean vs. ob/ob vs. TZD-treated ob/ob mice. In lean mouse muscles, 2-DOG uptake was stimulated by 82%, 95%, 165% (with 25, 100, 2000 U/ml insulin); muscles from ob/ob were severely insulin resistant (Ͻ80% stimulation with 2000 U/ml insulin). Muscles from TZD-treated ob/ob displayed a normal insulin response with 100 (71%) or 2000 (158%) U/ml insulin. Additional studies were performed using ZDF rats treated with/without TZD for 7 days. In vivo 2-DOG glucose uptake into soleus, gastrocnemius, and diaphragm muscles was measured during euglycemichyperinsulinemic clamp. Compared with lean rats, muscle 2-DOG uptake in ZDF was reduced by 52% (soleus) or 71% (diaphragm). Partial (40 -60%) normalization of the reduced 2-DOG uptake was evident in TZD-treated ZDF rats. In contrast to the effect of in vivo treatment on muscle insulin action, preincubation of isolated soleus muscles from naive lean or ob/ob mice for 5 h with 100 nM TZD did not affect insulin-stimulated 2-DOG uptake. We conclude: 1) PPAR␥ is expressed in myocytes within skeletal and cardiac muscle. 2) In vivo activation of PPAR␥ by treatment of insulin-resistant mice/rats with a potent TZD corrects impaired muscle insulin action.
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3) The lack of a direct effect on muscle after 5 h in vitro TZD incubation suggests that changes in insulin action may require a longer duration of PPAR␥ activation or that improved muscle insulin sensitivity may result from an indirect in vivo effect of PPAR␥ activation (e.g. changes in systemic lipid metabolism). (Endocrinology 139: 5034 -5041, 1998) T HIAZOLIDINEDIONES are a recently identified class of antidiabetic agents that improve glucose utilization without stimulating insulin release. These compounds function as insulin sensitizers and therefore have no potential to cause hypoglycemia (1) . Many studies have shown that oncea-day oral administration of thiazolidinediones to obese animal models of insulin resistance and NIDDM (e.g. db/db, ob/ob mice and Zucker fatty rats) can result in substantial correction of marked hyperglycemia and/or hyperinsulinemia (2) (3) (4) (5) . These effects on blood glucose and insulin are also accompanied by substantial lowering of high circulating triglyceride and nonesterified free fatty acid (FFA) levels. At least three thiazolidinedione compounds have been shown to enhance insulin sensitivity and improve glucose homeostasis in insulin-resistant human subjects (6 -8) .
Using cultured cell systems, thiazolidinediones have been shown to promote adipocyte differentiation and accelerate the induction of messenger RNAs (mRNAs) encoding adipocyte-specific genes such as fatty acid binding protein (aP2) (9, 10) . These findings led to the hypothesis that these compounds might function as agonists for a specific nuclear receptor-peroxisome proliferator-activated receptor ␥ (PPAR␥) that has been implicated in adipogenesis (11) . Two related isoforms (PPAR␥1 and PPAR␥2), which differ by the addition of 30 N-terminal amino acids in PPAR␥2, occur as a result of alternative promoter usage and mRNA splicing (12) .
Three related PPAR family members-PPAR␣, PPAR␥, and PPAR␦ (hNUC1)-exist and are subject to regulation by fatty acids and lipid metabolites. Individual PPARs heterodimerize with the retinoid ϫ receptor (RXR); the PPAR-RXR complex binds to specific DNA response elements (PPREs) in gene promoters and functions as a transcription factor that can be activated by either RXR-or PPAR-specific ligands. PPAR␥ is expressed at high levels in adipose tissue; it mediates transcriptional activation of the promoters for aP2 and other adipocyte genes and is sufficient to induce in vitro adipocyte differentiation (11, 13) .
Several lines of evidence implicate PPAR␥ activation as the predominant mechanism for thiazolidinedione action: 1) It is now clear that thiazolidinediones are high affinity PPAR␥-specific ligands that can serve to transactivate PPAR-responsive gene promoters (14) . 2) In vivo efficacy in rodents generally correlates with in vitro PPAR␥ activity (3, 15) . 3) Nonthiazolidinedione PPAR␥ agonists also exert antihyperglycemic effects in rodent NIDDM models (16, 17) . 4) Struc-turally distinct compounds that function as selective RXR ligands activate PPAR␥/RXR heterodimers and cause in vivo insulin sensitization in rodent NIDDM models (18). 5) Transcriptional activation of at least one gene (lipoprotein lipase) by PPAR␥ has been linked to one of the classic in vivo effects of thiazolidinedione: triglyceride lowering (19) .
Skeletal muscle is commonly viewed as the predominant tissue responsible for insulin mediated (in the fed state or during hyperinsulinemic clamp conditions) glucose disposal in both rat (20) and man (21) . Because treatment of insulinresistant humans and animals with thiazolidinediones has been shown to result in improved whole body glucose disposal under euglycemic hyperinsulinemic clamp conditions, substantial effects of insulin sensitizer therapy on insulin mediated glucose disposal in skeletal muscle can be implicated.
The potential effects of thiazolidinediones on muscle insulin sensitivity are not well characterized. Thus, it is unclear whether in vivo insulin sensitization is largely a secondary consequence of improvement in the abnormal metabolic milieu (e.g. FFA lowering) or whether there may be direct effects on insulin-responsive target tissues. We and others have reported the detection of PPAR␥ mRNA in skeletal muscles derived from mouse (22) , rat (23) , and man (23) (24) (25) (26) (27) . However, to date the presence of PPAR␥ protein within myocytes (in either cardiac or skeletal muscle) has not been determined. In addition, the hypothesis that activation of PPAR␥ can directly affect insulin action in intact skeletal muscles has not been tested. Here, we used immunohistochemistry with a PPAR␥-specific antiserum to characterize the expression of PPAR␥ protein in muscle. In addition, we used a potent, PPAR␥-selective thiazolidinedione to assess the effects of in vivo PPAR␥ activation on insulin action in skeletal muscle (both during euglycemic hyperinsulimic clamp and ex vivo in isolated soleus muscles). Finally, we assessed the potential for direct effects of PPAR␥ activation on muscle insulin action. Male ob/ob and lean control ob/ϩ mice (10 -12 weeks old from Jackson Laboratories, Bar Harbor, ME) and male Zucker diabetic fatty (ZDF) or control ZDF/ϩ lean rats (17 weeks old from Genetic Models, Inc., Indianapolis, IN) were allowed ad libitum access to water and Purina rodent chow (Ralston Purina, St. Louis, MO). The animals were untreated or dosed daily by oral gavage with vehicle (0.5% carboxymethylcellulose) or the TZD compound suspended in 0.5% carboxymethylcellulose at a specified mg of compound per kg animal weight. Normal Sprague-Dawley rats (6 weeks old from Jackson Laboratories) were were used for immunohistochemistry experiments.
Materials and Methods

Materials: animals
Localization of PPAR␥ protein in muscle by immunohistochemistry
Polyclonal antibodies specific for peptide SEKTQLYNRPHEEPSNS, which corresponds to amino acids 117-133 of human and mouse PPAR␥2, were generated in rabbits (Cocalico Biologicals, Inc., Reamstown, PA).
The antiserum recognized recombinant PPAR␥ by Western blotting and was tested for specificity using transiently transfected COS cells that express PPAR␥ or PPAR␣, or PPAR␦ (3) as follows. Cells grown on glass cover slides were fixed by first washing in PBS followed by incubation in 2% paraformaldehyde in 0.1 m phosphate buffer, pH 7.3, for 30 min. Fixed cells were washed 2 times in PBS containing 1% BSA (PBS/BSA) and nonspecific binding sites were blocked by incubation in Pierce (Rockford, IL) Superblock solution for 30 min followed by 2 ϫ washing with PBS/BSA. The blocked cells were permeabilized by incubation with 0.1% Triton X-100 for 10 min followed by 2 washes with PBS/BSA. Specific labeling was then carried out by incubation with 5 g/ml anti PPAR␥ IgG. To demonstrate antibody specificity, separate wells were incubated with immune IgG in the presence of 20 g/ml of immunizing peptide, an irrelevant peptide of similar length but unrelated sequence, or in the presence of nonimmune IgG. Incubation in primary antibody was carried out for 2 h at room temperature followed by 7 washes in PBS/BSA. Bound antibodies were visualized by incubation with a 1/200 dilution of Cappel FITC-goat antirabbit IgG for 60 min at room temperature followed by 7 washes with PBS/BSA. Following the final wash, cover slides were mounted using p-phenylenediamine mounting media (28) . Digital micrographs were taken using a Kodak Megaplex camera mounted on a Zeiss Axiophot microscope using a 63ϫ phase contrast objective.
Cardiac muscle samples were collected from 200 g male SpragueDawley rats under deep Nembutal anesthesia in which the abdominal aorta was cannulated in a retrograde direction. The vasculature and heart was cleared of blood by perfusion with saline and the heart muscle was fixed by perfusion with 50 ml of Nakane's (periodate/lysine/paraformaldehyde) fixative (29) . Following perfusion fixation, tissue samples (left ventricle) were obtained. In separate experiments samples of soleus and gastrocnemius muscle were collected from rats which had been similarly perfused via a cannula inserted into the right ventricle. Perfused tissues were then fixed an additional 10 h in Nakane's fixative. Muscle samples from a total of ten individual rats were examined by immunohistochemistry. Samples of human muscle were collected from the vastus lateralis portion of the quadriceps femorus under local anesthesia (mepivacain chloride 5 mg/ml). Upon excision, the muscle specimens were cleaned of connective tissue and placed in Nakane's PLP fixative (within 15 min) for 6 h. The study protocol was reviewed and approved by the Institutional Ethical Committee of the Karolinska Institute, and informed consent was obtained from all subjects before participation. Skeletal muscle samples from three normal men (mean BMI 27.4 Ϯ 1.8 kg/m 2 ; mean age 55 Ϯ 3 yr) were examined. Following fixation, all samples were cryoprotected by sequential incubation in: 10% sucrose in 0.05 m phosphate buffer, pH 7.3, (1 h), 15% sucrose in 0.05 m phosphate buffer, pH 7.3, (4 -12 h), 20% sucrose in 0.05 m phosphate buffer pH 7.3, (4 h), 20% sucrose plus 5% glycerol in 0.05 m phosphate buffer, pH 7.3, (1 h). Cryoprotected specimens were embedded in OCT medium (Miles) and rapidly frozen in liquid nitrogen and stored at Ϫ70 C until use. Cryosections (6 ) were cut on a ReichertJung Cryocut 1800 equipped with a cryostat sectioning aid (Instumedics, Inc., Teaneck, NJ). All sections were pretreated with 3% H 2 O 2 in methanol for 20 min to inactivate endogenous peroxidases, followed by 0.1% Triton-X 100 in PBS to increase permeability. Putative endogenous biotin binding was blocked with avidin solution (Vector Laboratories, Inc., Burlington, CA), followed by extensive washing in rinse buffer (0.1 m phosphate buffer, pH 7.8, containing 0.5% BSA and 0.01% Tween-20). Endogenous avidin binding sites were then blocked with biotin solution (Vector Laboratories, Inc., Burlingame, CA). Possible nonspecific staining was inhibited by preincubating the slides for 30 min in 1% normal donkey serum (Jackson Labs), followed by extensive washing in rinse buffer. To further reduce nonspecific labeling, sections were incubated for 30 min in a solution of 5% Carnation nonfat dry milk containing 0.1% BSA and 0.04% Na azide in 0.1 m phosphate buffer, pH 7.8. This solution was centrifuged for 5 min at 13000 rpm just before use.
Sections were immunolabeled by incubation with the primary PPAR␥-specific antibody described above. Primary antibody incubations were carried out at a concentration of 1 g/ml IgG in rinse buffer for 60 min at room temperature. Incubation was terminated by extensive washing in rinse buffer. Bound antibodies were detected via immunoperoxidase microscopy using the ABC technique (Elite kit; Vector Laboratories, Inc.) with the following modifications. Primary antibody was visualized using affinity purified biotinylated F(abЈ)2 fragments of don-key antirabbit IgG from Jackson Labs. Peroxidase reaction product was developed with a glucose oxidase/DAB/nickel method to provide maximum sensitivity. In some cases eosin was used as a counterstain. Labeled sections were then dehydrated, cleared, and mounted with Permount. Digital micrographs were taken using a Kodak Megaplex camera mounted on a Zeiss Axiophot microscope using a 63ϫ phase contrast objective.
Measurement of in vivo muscle 2-deoxyglucose uptake during hyperinsulinemic euglycemic clamp
Hyperinsulinemic euglycemic clamps were performed in 17-weekold Zucker diabetic fatty (ZDF) rats and Zucker/lean rats. The TZD compound was administered to ZDF rats by oral gavage at a daily dose of 10 mg/kg for 7-11 days. Sodium Nembutal-anesthetized rats were cannulated in the left jugular vein for constant rate infusion of insulin (25 mU/kg⅐min) and 3 H-glucose (New England Nuclear, Boston, MA). The right jugular vein was cannulated for variable rate infusion of glucose to maintain euglycemia; the left femoral vein was cannulated for bolus infusions of 3 H-glucose and 14 C-2-deoxyglucose (NEN). Blood samples were obtained from the cannulated left femoral artery for determination of plasma glucose levels and 3 H and 14 C radioactivity. The rate of 14 C-2-deoxyglucose uptake into selected skeletal muscles was determined as previously described (30).
2-Deoxyglucose uptake in isolated in vitro incubated soleus muscles
All media were prepared from a stock solution of Krebs-Henseleit buffer (KHB) containing 5 mm HEPES and 0.1% BSA (RIA grade). The gas phase in the vial was maintained at 95% O 2 /5% CO 2 throughout all incubations. To assess the effects of prior in vivo TZD treatment on in vitro 2-deoxyglucose uptake, isolated soleus muscles from lean ob/ϩ, ob/ob, or TZD-treated ob/ob mice were incubated for 20 min in KHB containing 20 mm mannitol, and the specific additions as described for each experiment in the figure legends. Thereafter, glucose uptake was assessed for 20 min as previously described (31) . Muscles were incubated in KHB containing 1 mm 2-deoxy- [1,2, 3 H]glucose (2.5 Ci/ml) and 19 mm [
14 C]mannitol (0.35 Ci/ml). 2-deoxyglucose uptake has been reported to directly reflect glucose transport and not metabolism in mouse skeletal muscle when performed under the present conditions (31) . Following the incubations, the muscles were processed as described by Wallberg-Henriksson et al. (32) for the rat epitrochlearis muscle. Values are expressed as micromoles of 2-deoxyglucose per milliliter of intracellular water per hour.
Additional experiments were performed to assess whether TZD had a direct effect on insulin-stimulated 2-deoxyglucose uptake in skeletal muscle. Isolated soleus muscles from lean ob/ϩ or ob/ob mice were preincubated for 5 h in the presence or absence of 100 nm TZD. TZD concentration was maintained throughout all incubations. A stock solution of TZD was prepared in dimethylsulfoxide (DMSO) before addition to KHB. The final concentration of DMSO was adjusted to 0.002% in each incubation medium. Preincubation media was supplemented with 8 mm glucose and 12 mm mannitol. The media was changed after 2.5 h. Muscles were transferred to glucose-free KHB, which contained 25 or 2000 U/ml insulin and incubated for 20 min. Thereafter, muscles were incubated to assess 2-deoxyglucose uptake as described above.
Results
Detection of PPAR␥ protein in skeletal and cardiac muscle
To determine the specificity of our anti-PPAR␥ peptide antibody, COS-1 cells were plated on slides and transfected with pSG5, pSG5-hPPAR␥2, pSG5-hPPAR␦, or pSG5-hPPAR␣. After 48 h, the cells were permeabilized, exposed to the antibody and examined by immunofluorescent microscopy. Predominant nuclear staining of cells was observed only in the nuclei of cells transfected with hPPAR␥2 (not shown). Additional experiments demonstrated that the signal observed by immunofluorescence was completely blocked by immunizing peptide. As predicted by the epitope used for immunization, the antibody recognized both PPAR␥1 and PPAR␥2 by Western blot in differentiated 3T3L1 cells (not shown).
To visualize the distribution of PPAR␥ in skeletal muscle, cryostat sections of perfusion fixed rat soleus muscles (considered to be predominantly red muscle fibers) were incubated with anti-PPAR␥ antibody followed by immunoperoxidase labeling. The results (Fig. 1) demonstrate that immunoperoxidase reaction product was easily seen within the nuclei of individual myocytes. Reaction product was also often seen within the nuclei of adjacent vascular endothelial cells. Reaction product was not detected in the cytoplasmic areas of either the myocytes or the capillary endothelial cells. The labeling of myocyte nuclei was very specific in that simultaneous incubation with immunizing peptide completely blocked labeling whereas incubation with a peptide of similar size but unrelated sequence had no effect on the intensity of the label. In addition, incubation with nonimmune IgG did not label this tissue.
To determine if PPAR␥ was differentially distributed between red and white skeletal muscle fibers, samples were also collected from the lateral head of rat gastrocnemius muscles (considered to be composed primarily of white muscle fibers). The results ( Fig. 2A) were similar to those obtained with soleus muscles, demonstrating that, within the limits of this method, both skeletal muscle fiber types contain roughly equal amounts of immunodetectible PPAR␥. In addition, we determined that there was a similar level of PPAR␥ expression in the nuclei of cardiac (left ventricle) myocytes (Fig. 2B) . In all three sets of muscles, immunolabeling was restricted to the nuclei and was not found associated with any other cytoplasmic structures or with the contractile apparatus.
To extend these observations to humans, muscle tissue biopsies from human donors were also examined using the same immunolabeling approach. The results (Fig. 3) demonstrated that PPAR␥ could be visualized within the nuclei of the myofiber syncytium of the quadriceps muscle. Because these samples were examined and recorded by direct microscopic observation, it is clear that the label is actually within the nuclei of the myocytes themselves and could not be confused with nuclei of adipose tissue, which is sometimes closely associated with skeletal muscle.
In all cases, the specificity of the immunoperoxidase label was verified by three independent criteria. 1) The ability of the primary antibody to immunoperoxidase label these tissues was completely blocked by simultaneous incubation with immunizing peptide. 2) The ability of primary antibody to label was unaffected by incubation with an irrelevant peptide of the same molecular weight. 3) Neither preimmune nor nonimmune IgG at equivalent concentrations labeled these tissues.
Effect of TZD treatment on in vivo muscle 2-deoxyglucose uptake in ZDF rats
Based upon results from hyperinsulinemic euglycemic clamp studies, ZDF rats displayed profound hyperglycemia and insulin resistance that was substantially corrected by 7-11 day treatment with the TZD compound (10 mg/kg-day). Elevated levels of free fatty acids were suppressed following 1-2 days of treatment and elevated plasma triglycerides were suppressed after 4 days in TZD treated ZDF rats (data not shown). Mean nonfasting and fasting plasma glucose levels in ZDF rats were 481 and 346 mg/dl, respectively, compared with 116 mg/dl for both nonfasting and fasting levels in nondiabetic Zucker/lean rats. The TZD dosing regimen resulted in 60% correction of both nonfasting (266 mg/dl) and fasting (199 mg/dl) hyperglycemia. The glucose infusion rate necessary to maintain euglycemia in the presence of extreme hyperinsulinemia induced in all rats was 22.2 mg/kg⅐min in Zucker/lean rats compared with only 4.1 mg/kg-min in ZDF rats. TZD dosing for 7-11 days elicited a 100% correction of this parameter. Skeletal muscle uptake of 2-deoxyglucose during the terminal euglycemic phase was determined in each rat; a moderate to severe reduction in insulin-stimulated glucose uptake was evident in several muscles from ZDF vs. Zucker/lean rats (see Fig. 4 ). Uptake of 2-deoxyglucose in soleus was decreased 50% in ZDF rats compared with Zucker/lean rats, and TZD treatment resulted in a mean value that was corrected by 60%. This value did not reach statistical significance, possibly due to the small sample size. Uptake of 2-deoxyglucose in diaphragm from ZDF rats was reduced by 71% relative to Zucker/lean rats; this parameter was corrected by 62% in TZD-treated ZDF rats. In contrast to the reduced 2-deoxyglucose uptake in soleus and diaphragm from ZDF rats, glucose uptake in gastrocnemius was not significant different between ZDF and Zucker/lean rats. However, TZD administration resulted in a significant (47%) increase compared with untreated ZDF rats.
Effect of in vivo TZD treatment on soleus muscle insulin action in ob/ob mice
Mean nonfasting blood glucose levels were 129 Ϯ 5 and 331 Ϯ 28 mg/dl for lean ob/ϩ and ob/ob mice, respectively. Four days of oral TZD treatment (10 mg/kg⅐day) lowered nonfasting blood glucose in ob/ob mice to 93 Ϯ 3 mg/dl. To examine the effects of oral TZD treatment on in vitro glucose uptake, isolated soleus muscles from lean ob/ϩ, ob/ob or TZDtreated ob/ob mice were incubated in the presence or absence of insulin and 2-deoxyglucose uptake was determined (Fig.  5) . Basal, submaximal, and maximal insulin-stimulated 2-deoxyglucose uptake was markedly and significantly reduced in soleus muscles from ob/ob compared with lean mice. Maximal insulin-stimulated 2-deoxyglucose uptake was reduced by 73% in soleus muscles from ob/ob vs. lean mice. Basal glucose transport activity in soleus muscle was fully restored to control levels in ob/ob mice following TZD treatment. Furthermore, insulin-stimulated rates of glucose transport (100 and 2,000 U/ml) were completely normalized in ob/ob mice following TZD treatment. Submaximal insulinstimulated (25 U/ml) glucose uptake rates were also improved, but not completely normalized to control levels in soleus from TZD-treated ob/ob mice.
Assessment of soleus muscles insulin action after in vitro incubation with TZD
We next tested the hypothesis that enhanced insulin action on glucose uptake in soleus muscles derived from TZDtreated ob/ob mice was due to a direct effect of the compound on skeletal muscle. Isolated soleus muscles from untreated lean ob/ϩ or ob/ob mice were preincubated in 100 nm TZD for 5 h, followed by a 40 min exposure to 25 or 2000 U/ml insulin. 2-deoxyglucose uptake was assessed during the final 20 min. Under these conditions, TZD exposure was without effect on insulin-stimulated 2-deoxyglucose uptake (Fig. 6) .
In addition, we measured insulin-stimulated (25 and 2000 U/ml) [U- 14 C]glucose incorporation into glycogen in soleus muscles (n ϭ 4, each) derived from lean ob/ϩ or ob/ob mice with and without 5 h in vitro incubation with 100 nm TZD using established methods (33, 34) . Compared with control muscles, muscles from ob/ob mice were severely resistant to this effect of insulin and there was no effect of TZD incubation on insulin-stimulated glycogen synthesis in either normal or insulin-resistant muscles (data not shown).
It should be noted that the concentration (100 nm) of the specific TZD compound employed in the above noted experiments was empirically determined to be 10-fold higher than the concentration required for maximal activation of PPAR␥-mediated transcription under two experimental conditions: 1) functional activation of a Gal4-PPAR␥ ligandbinding-domain chimeric receptor in transfected COS cells (J. Berger, unpublished); 2) stimulation of adipocyte fatty acid binding protein (aP2) mRNA expression in cultured 3T3-L1 preadipocytes (B. Zhang, unpublished).
Discussion
PPAR␥ is highly expressed in adipose tissue, but lower levels of PPAR␥ mRNA expression have been detected in skeletal muscle of rodents and man (22) (23) (24) (25) (26) (27) . In addition, there may be higher levels of PPAR␥ mRNA expression in skeletal muscle derived from nondiabetic obese or obese NIDDM subjects (23, 24, 27) . One shortcoming of previous studies is that the contribution of contaminating adipocyte-derived PPAR␥ mRNA to the net amount of PPAR␥ mRNA detected in samples of muscle tissue cannot be excluded. To date, there are no published reports of PPAR␥ protein expression in muscle. We used antipeptide antibodies that were specific for PPAR␥ and immunoperoxidase labeling to clearly demonstrate the presence of PPAR␥ protein within the nuclei of individual myocytes from both red and white skeletal muscle fiber types in rat and human vastus lateralis. Although the signal appeared strong relative to what one might expect from previously reported low levels of PPAR␥ mRNA, the immunoperoxidase methods we used included an amplification step. For technical reasons, we were unable to use immunoperoxidase staining to compare PPAR␥ protein abundance in fat vs. muscle. Nevertheless, this finding provides a potential means by which TZD PPAR␥ agonists could exert direct insulin sensitizing effects in muscle. We also established that PPAR␥ protein was present in nuclei of left ventricular rat cardiomyocytes. This result provides an important insight into a potential PPAR␥-mediated toxicity because TZD insulin sensitizers were shown to cause cardiac hypertrophy in preclinical animal studies (35) .
In addition to the well described effect of TZD PPAR␥ agonists in improving whole-body insulin sensitivity in insulin-resistant animals and humans, in vivo treatment with these compounds can reverse discrete defects in tissue insulin action. Thus, several studies showed that in vivo treatment of insulin-resistant mice or rats was associated with improved insulin-stimulated glucose uptake in adipocytes derived from treated animals (4, 5, 36, 37) . In some cases, this was associated with up-regulation of previously suppressed GLUT4 levels (5, 36) . The effects of TZD treatment on insulin action in muscle have not been well characterized.
In the present study, we used a potent and highly selective TZD PPAR␥ agonist (3) to demonstrate that in vivo treatment of insulin-resistant rats or mice could affect skeletal muscle insulin sensitivity. In ZDF rats with extreme hyperglycemia and insulin resistance, in vivo treatment with this TZD fully normalized whole-body glucose uptake under hyperinsulinemic clamp conditions. This positive effect coincided with significant improvement in in vivo 2-deoxyglucose glucose 
FIG. 4.
In vivo TZD treatment augments muscle glucose uptake during hyperinsulinemic-euglycemic clamp in ZDF rats. Clamp studies were performed as described in Materials and Methods. Oral administration of the TZD compound was at a dose of 10 mg/kg⅐day for 7-11 days. The data represent mean Ϯ SEM values for 6 ZDF control rats, 6 TZD dosed ZDF rats, and 5 Zucker/lean rats. Results were significantly different from control ZDF rats with p values of: *, P Ͻ 0.05 and **, P Ͻ 0.01.
FIG. 5.
In vivo TZD treatment of ob/ob mice corrects insulin-resistant glucose uptake in isolated soleus muscles. Isolated soleus muscles from lean ob/ϩ, ob/ob, or TZD-treated ob/ob mice (10 mg/kg⅐day for 4 days) were preincubated at 30 C for 20 min in KHB containing 0, 25, 100, or 2000 U/ml insulin. Thereafter, muscles were incubated for 20 min to assess 2-deoxyglucose uptake. Values represent mean Ϯ SEM for 4 -6 muscles per group. Results were significantly different from lean mice at each insulin concentration with p values of *, P Ͻ 0.05 and **, P Ͻ 0.01, and from both lean and ob/ob mice with P values of #, P Ͻ 0.05. Similar results were obtained in two additional experiments.
uptake into both diaphragm and gastrocnemius muscles and a trend toward improved glucose uptake in soleus muscle. Our experiments with ob/ob mice showed that 4 days of TZD treatment was sufficient to normalize hyperglycemia and that this improvement was associated with normalization of severely insulin-resistant glucose uptake measured ex vivo in soleus muscles derived from treated and untreated mice. These results indicate that improved insulin action in skeletal muscle is a clear consequence of in vivo TZD treatment that is likely to substantially contribute to net effects on insulinstimulated glucose metabolism. To our knowledge, there are only two prior reports where changes in muscle insulin sensitivity per se were shown after in vivo TZD treatment: 1) Chronic treatment of high fat-fed rats with a potent TZD (BRL 49653) resulted in improved in vivo glucose uptake into skeletal muscles under clamp conditions (38) . 2) Chronic in vivo TZD administration enhanced insulin responsiveness of soleus muscles derived from dexamethasone-treated rats (39) . A key unresolved question concerns the potential for direct effects of TZDs (PPAR␥ activation) on insulin-responsive target tissues. Specifically, the hypothesis that TZDs might have direct effects on intact muscle tissue has not been previously assessed. In the present study, the potent TZD PPAR␥ agonist was used to assess the potential for direct effects on isolated soleus muscles. After a 5-h incubation period (similar results, not shown, were obtained up to 9 h), there was no TZD effect on maximal or submaximal insulinmediated glucose uptake in muscles derived from either lean or ob/ob mice. In addition, insulin-stimulated glucose incorporation into glycogen was unaffected by exposure to the TZD. Thus, despite the presence of PPAR␥ protein within this tissue, there was no apparent direct effect of PPAR␥ activation during this 5-h interval to potentiate insulin-stimulated glucose uptake and storage as glycogen. In contrast, we previously observed that in vitro incubation of isolated rat adipose tissue with precisely the same TZD at the same (or lower) concentration could clearly potentiate insulin-stimulated glucose incorporation into glycogen and activation of glycogen synthase within a 2-3 h incubation time period (40) . Obviously, longer term exposure to TZDs may be required for possible direct insulin sensitizing effects in this tissue because PPAR␥ mediated effects are presumed to be based on changes in gene expression. Two prior studies have reported that chronic incubation (20 -24 h) of cultured muscle cells (cardiomyocytes or BC3H-1 myocytes) with TZDs resulted in an increase in glucose transport (41, 42) . However, both studies noted that there was a substantial increase in GLUT-1 expression, and in neither case was insulin responsiveness definitively affected. We have also observed that incubation of L6 myotubes, an insulin-responsive muscle cell line, with various TZDs did not potentiate insulin-stimulated glucose uptake in a significant manner (J. Berger, unpublished) .
In summary, we have definitively established that PPAR␥ is expressed in skeletal and cardiac myocytes and we have used two approaches to demonstrate that in vivo administration of a TZD PPAR␥ agonist results in improved insulinstimulated skeletal muscle glucose uptake. Because there was no apparent direct effect of a 5-h exposure of soleus muscles to a potent PPAR␥ agonist upon insulin-stimulated muscle glucose uptake, we suggest that a meaningful response of skeletal muscle to PPAR␥ activation may require longer exposure to PPAR␥ agonist. In recently completed additional studies conducted by Wu et al. using ZDF rats, high doses of potent PPAR␥ agonists resulted in substantial improvement of in vivo insulin-mediated skeletal muscle glucose uptake after 7-11 days but not after 1-2 days of daily oral treatment (43) . Alternatively, the in vivo effect of TZD treatment on muscle insulin action may predominantly occur as a secondary consequence of the improved metabolic milieu. Thus, lowering of elevated FFA and triglyceride levels, as well as partial improvements in elevated glucose and insulin levels that may be mediated by effects of PPAR␥ activation in fat (and direct or indirect effects on the liver), could act in concert to restore muscle insulin sensitivity. 
